{"entity":{"id":"adora2a","kind":"target","name":"Adenosine A2A receptor (ADORA2A)","aka":["A2AR","A2A receptor","adenosine A2a receptor","RDC8"],"tldr":"The A2A receptor is where adenosine lands on a T cell and tells it to rest. Oral antagonists, cousins of caffeine, are in phase 2 combinations with PD-1 blockade and chemotherapy.","summary":"ADORA2A (chromosome 22q11.23) encodes a G-protein-coupled adenosine receptor whose activity is mediated by G proteins that activate adenylyl cyclase (UniProt P29274). Ectonucleotidases and adenosine receptors are broadly expressed and have emerged as immuno-oncology targets, with early-phase trials showing promising results (Allard et al. 2019, Immunol Rev). Ciforadenant is in phase 1b/2 with ipilimumab and nivolumab (NCT05501054), etrumadenant (A2A/A2B) in phase 2 combinations in pancreatic cancer (NCT06048484), and inupadenant in phase 2 with chemotherapy in non-squamous non-small-cell lung cancer (NCT05403385).","asOf":"2026-09-24","links":[{"label":"HGNC HGNC:263","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:263"},{"label":"UniProt P29274","url":"https://www.uniprot.org/uniprotkb/P29274/entry"},{"label":"NCBI Gene 135","url":"https://www.ncbi.nlm.nih.gov/gene/135"},{"label":"Allard et al. 2019, Immunol Rev (Europe PMC)","url":"https://europepmc.org/article/MED/29758241"}],"tags":["checkpoint-map"],"related":["cd73-adenosine","entpd1"],"cancers":["pancreatic","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["cancer-immunity-cycle"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Prevalence not recorded: HGNC and UniProt carry no positivity rates."],"provenance":{"editedBy":"OnCo checkpoint map (HGNC REST, UniProt REST, ClinicalTrials.gov v2)","editedOn":"2026-09-24"},"symbol":"ADORA2A","role":["immune-checkpoint"],"sources":[{"label":"HGNC HGNC:263","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:263","note":"approved symbol, name, aliases and cross-references"},{"label":"UniProt P29274","url":"https://www.uniprot.org/uniprotkb/P29274/entry","note":"protein name, function and tissue specificity"}],"specificitySources":[],"hgnc":"HGNC:263","ensembl":"ENSG00000128271","uniprot":"P29274","entrez":"135","biology":"The receptor end of the CD39-CD73-adenosine axis; antagonists are small molecules.","whereFound":["Broadly expressed, per Allard et al. 2019; UniProt records no human tissue distribution","Pancreatic and non-small-cell lung cancer trials of antagonists"],"targetClass":"surface-antigen","prevalence":[]},"route":"/targets/adora2a/","neighbours":{"target":[{"id":"entpd1","kind":"target","name":"CD39 (ENTPD1)","route":"/targets/entpd1/"},{"id":"cd73-adenosine","kind":"target","name":"CD73 / adenosine axis","route":"/targets/cd73-adenosine/"}],"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"pathway":[{"id":"cancer-immunity-cycle","kind":"pathway","name":"The cancer-immunity cycle","route":"/pathways/cancer-immunity-cycle/"}],"term":[{"id":"checkpoint","kind":"term","name":"Checkpoint (two meanings)","route":"/terms/checkpoint/"}]}}